A combined federal challenge of the role that drug manufacturers and distributors played in the opioid epidemic now has more than 320 lawsuits; Ohio prepares a request to add Medicaid work requirements, while a California lawmaker introduces a bill to block the state from doing so; a trial of an Alzheimer drug is being expanded to add more patients in order to clarify the results.
There are now more than 320 lawsuits that have been brought against drug manufacturers and distributors regarding opioids. According to AP, a federal judge in Cleveland is overseeing the consolidated lawsuits and just allowed 12 more into the case. The lawsuits allege that the drug manufacturers and distributors did not do enough to prevent the opioid epidemic and, therefore, should bear responsibility for it.
In California, a legislator has introduced a bill that would prevent the state from seeking a waiver to impose work requirements in the Medicaid program. The bill would also bar the state from trying to impose waiting periods or time limits on coverage, reported Los Angeles Times. Meanwhile, Ohio is preparing to ask the government to grant permission for the state to add a work requirement. The Columbus Dispatch reported that people over the age of 55, in school or training for work, seeking addiction treatment, or with intensive healthcare needs or serious mental illness would be exempt from the work requirement.
One day after Merck ended its Alzheimer disease trial because the drug had little effect, Biogen announced it would add patients to its trial of aducanumab. Approximately 500 more patients will be added to the trial to help clarify the results of the trial, according to Bloomberg. Biogen’s chief medical officer explained that there was more variability on the primary endpoint than expected. Expanding the trial raises concerns that the results had been poor.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More